BIOAGE LABS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
BIOAGE LABS, INC. (BIOA) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value of $66.60 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue · last filed 2026-08-05
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $66.60M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $36.01M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $18.91M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $1.69M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value |
|---|---|
| 2026-06-30 | $66.60M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $36.01M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $18.91M 10-K · filed 2026-03-24 |
| 2025-09-30 | $1.69M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $265.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $155.00K 10-Q · filed 2025-05-06 |
| 2024-12-31 | $966.00K 10-K · filed 2025-03-20 |
| 2024-09-30 | $24.83M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |